9 unknown, 3 not yet recruiting, 2 recruiting. 10 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Unknown 6, Not yet recruiting 3, Recruiting 1 |
| Phase 1 | 3 | Unknown 2, Recruiting 1 |
| Phase 3 | 2 | Unknown 2 |
Follow HX008: new trials by email Literature Review of HX008 trials Research Report on HX008
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma Becotatug Vedotin (MRG003), Pucotenlimab - Oral Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 32 | 2026-09-01 | 2026-08-17 |
| Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive Becotatug Vedotin, Pucotenlimab - Advanced Refractory Solid Tumors, EGFR Gene Overexpression | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 32 | 2026-08-01 | 2026-07-17 |
| Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II Becotatug Vedotin, Pucotenlimab - Biliary Tract Cancer (BTC), EGFR-positive Advanced Biliary Tract Carcinoma | Phase 2 | Not yet recruiting | HuiKai Li | 30 | 2026-07-01 | 2026-06-16 |
| MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma MRG003, HX008 - Penile Cancer | Phase 1 | Recruiting | Jiyan Liu | 10 | 2026-02-12 | 2026-04-07 |
| Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma Pucotenlimab, Becotatug Vedotin - Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 2 | Not yet recruiting | Fudan University | 38 | 2026-01-09 | 2026-02-06 |
| Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC) HX008, Bevacizumab, Lenvatinib - Hepatocellular Carcinoma | Phase 2 | Unknown | Taizhou Hanzhong biomedical co. LTD | 72 | 2021-01-07 | 2021-02-05 |
| Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC) HX008 - Anaplastic Thyroid Cancer | Phase 2 | Unknown | Taizhou Hanzhong biomedical co. LTD | 66 | 2020-12-28 | 2020-10-05 |
| HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer HX008, Pembrolizumab, pemetrexed - Nonsquamous Non-small Cell Lung Cancer | Phase 2 / Phase 3 | Unknown | Taizhou Hanzhong biomedical co. LTD | 700 | 2020-09-25 | 2021-02-11 |
| Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer HX008 - Bladder Cancer | Phase 2 | Unknown | Taizhou Hanzhong biomedical co. LTD | 110 | 2020-09-25 | 2021-02-04 |
| HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer Irinotecan Hydrochloride Injection, HX008, Placebo - Stomach Cancer | Phase 3 | Unknown | Taizhou Hanzhong biomedical co. LTD | 560 | 2020-09-16 | 2021-01-28 |
| A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma HX008, LP002 - Melanoma | Phase 1 | Unknown | Taizhou HoudeAoke Biomedical Co., Ltd. | 63 | 2020-08-20 | 2021-02-16 |
| A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors HX008 - Advanced Solid Tumor | Phase 1 | Unknown | Taizhou Hanzhong biomedical co. LTD | 30 | 2019-09-05 | 2021-04-01 |
| A Study of HX008 for the Treatment of Patients With Malignant Melanoma HX008 - Melanoma | Phase 2 | Unknown | Taizhou Hanzhong biomedical co. LTD | 119 | 2018-11-08 | 2021-02-11 |
| Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors Anti-PD-1 monoclonal antibody - Advanced Solid Tumor | Phase 2 | Unknown | Taizhou Hanzhong biomedical co. LTD | 123 | 2018-09-30 | 2021-03-04 |
Melanoma (2) · Biliary Tract Neoplasms (1) · Carcinoma, Hepatocellular (1) · Head and Neck Neoplasms (1) · Penile Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1) · Thyroid Carcinoma, Anaplastic (1) · Urinary Bladder Neoplasms (1)
Taizhou Hanzhong biomedical co. LTD (8) · Fudan University (1) · HuiKai Li (1) · Jiyan Liu (1) · Sun Yat-sen University (1) · Taizhou HoudeAoke Biomedical Co., Ltd. (1) · Tianjin Medical University Second Hospital (1)
China (13)
Haitao Wang, Ph.D. (1) · Jun Guo, MD (1)